GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003110021 | Liver | HCC | animal organ regeneration | 54/7958 | 76/18723 | 4.31e-07 | 7.22e-06 | 54 |
GO:190121412 | Liver | HCC | regulation of neuron death | 179/7958 | 319/18723 | 5.65e-07 | 9.01e-06 | 179 |
GO:200011612 | Liver | HCC | regulation of cysteine-type endopeptidase activity | 137/7958 | 235/18723 | 6.91e-07 | 1.08e-05 | 137 |
GO:005254722 | Liver | HCC | regulation of peptidase activity | 247/7958 | 461/18723 | 8.28e-07 | 1.27e-05 | 247 |
GO:000726521 | Liver | HCC | Ras protein signal transduction | 187/7958 | 337/18723 | 8.89e-07 | 1.35e-05 | 187 |
GO:00518172 | Liver | HCC | modulation of process of other organism involved in symbiotic interaction | 56/7958 | 81/18723 | 1.11e-06 | 1.65e-05 | 56 |
GO:005254822 | Liver | HCC | regulation of endopeptidase activity | 230/7958 | 432/18723 | 3.58e-06 | 4.68e-05 | 230 |
GO:00518512 | Liver | HCC | modulation by host of symbiont process | 43/7958 | 60/18723 | 4.48e-06 | 5.66e-05 | 43 |
GO:000724912 | Liver | HCC | I-kappaB kinase/NF-kappaB signaling | 156/7958 | 281/18723 | 6.66e-06 | 8.00e-05 | 156 |
GO:00301932 | Liver | HCC | regulation of blood coagulation | 46/7958 | 66/18723 | 7.12e-06 | 8.47e-05 | 46 |
GO:004312312 | Liver | HCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 108/7958 | 186/18723 | 1.28e-05 | 1.43e-04 | 108 |
GO:003582111 | Liver | HCC | modulation of process of other organism | 67/7958 | 106/18723 | 1.34e-05 | 1.48e-04 | 67 |
GO:00517022 | Liver | HCC | biological process involved in interaction with symbiont | 60/7958 | 94/18723 | 2.41e-05 | 2.54e-04 | 60 |
GO:19000462 | Liver | HCC | regulation of hemostasis | 46/7958 | 68/18723 | 2.43e-05 | 2.56e-04 | 46 |
GO:004312212 | Liver | HCC | regulation of I-kappaB kinase/NF-kappaB signaling | 138/7958 | 249/18723 | 2.47e-05 | 2.58e-04 | 138 |
GO:00508182 | Liver | HCC | regulation of coagulation | 47/7958 | 71/18723 | 4.68e-05 | 4.50e-04 | 47 |
GO:004206022 | Liver | HCC | wound healing | 219/7958 | 422/18723 | 5.34e-05 | 5.04e-04 | 219 |
GO:005140212 | Liver | HCC | neuron apoptotic process | 135/7958 | 246/18723 | 5.64e-05 | 5.26e-04 | 135 |
GO:000689821 | Liver | HCC | receptor-mediated endocytosis | 134/7958 | 244/18723 | 5.73e-05 | 5.31e-04 | 134 |
GO:005165112 | Liver | HCC | maintenance of location in cell | 119/7958 | 214/18723 | 7.11e-05 | 6.39e-04 | 119 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa0481028 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa05130310 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa04810112 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513022 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513032 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0513042 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa046112 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
hsa0513052 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481051 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa0461111 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F2R | SNV | Missense_Mutation | | c.978N>G | p.Phe326Leu | p.F326L | P25116 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
F2R | SNV | Missense_Mutation | | c.253N>A | p.Pro85Thr | p.P85T | P25116 | protein_coding | tolerated(0.39) | benign(0.005) | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
F2R | SNV | Missense_Mutation | novel | c.1106N>C | p.Leu369Pro | p.L369P | P25116 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AO-A0JI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
F2R | SNV | Missense_Mutation | | c.250N>T | p.Leu84Phe | p.L84F | P25116 | protein_coding | tolerated(0.69) | benign(0.063) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
F2R | SNV | Missense_Mutation | | c.238N>G | p.Leu80Val | p.L80V | P25116 | protein_coding | tolerated(0.55) | benign(0.039) | TCGA-BH-A1FM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
F2R | insertion | Frame_Shift_Ins | novel | c.391_392insACACTACCAGGCTCTGCTCTGCTGTCTCTGAGTTGGTACTACTC | p.Met131AsnfsTer16 | p.M131Nfs*16 | P25116 | protein_coding | | | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD |
F2R | SNV | Missense_Mutation | | c.299N>C | p.Trp100Ser | p.W100S | P25116 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
F2R | SNV | Missense_Mutation | novel | c.727N>C | p.Thr243Pro | p.T243P | P25116 | protein_coding | deleterious(0) | probably_damaging(0.936) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
F2R | SNV | Missense_Mutation | novel | c.517N>A | p.Glu173Lys | p.E173K | P25116 | protein_coding | tolerated(0.57) | benign(0.096) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
F2R | SNV | Missense_Mutation | | c.1210N>G | p.Met404Val | p.M404V | P25116 | protein_coding | tolerated(0.19) | benign(0) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | inhibitor | CHEMBL2013119 | RIGOSERTIB SODIUM | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | | TYROSINE KINASE INHIBITOR | | 15383630 |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | | MORPHINE | MORPHINE | 12373743 |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | | ETHANOL | ALCOHOL | 16930224 |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | 405560412 | | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | CHEMBL2103856 | ATOPAXAR | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | CHEMBL2107386 | VORAPAXAR SULFATE | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | | WORTMANNIN | WORTMANNIN | 10318860,7559410,8955143 |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | 178100871 | VORAPAXAR | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | agonist | 178100667 | | |